Liquidia Corporation is a small U.S. biotechnology company focused on the treatment of pulmonary arterial hypertension (PAH). Its main product, Yutrepia, is an innovative inhaled formulation of treprostinil based on its proprietary PRINT technology, which enables precise particle engineering and more efficient delivery of the drug into the lungs. Liquidia aims to provide patients with a more convenient and cost-effective alternative to established therapies such as Tyvaso from United Therapeutics, positioning itself as a potential disruptor in the market. Although the company has significantly smaller financial resources and is not yet profitable, the success of Yutrepia and potential portfolio expansion could secure rapid growth and capture part of the multi-billion-dollar PAH treatment segment.